Efficacy of a digital mental health intervention embedded in routine care compared with treatment as usual in adolescents and young adults with moderate depressive symptoms: protocol for randomised controlled trial

• Published in: BMJ open 2023-03, Vol.13 (3), p.e067141-e067141
• Main Authors: Szigethy, Eva, Wolfson, David, Sinclair-McBride, Keneisha, Williams, Kelly, Jhe, Grace, Lee, Erica H, Bialostozky, Mario, Wallace, Meredith, Bhatnagar, Sonika, Demaso, DR, Yealy, Donald M, Hollenbach, Kathryn
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Antidepressants; Anxiety - therapy; Anxiety Disorders; Behavior modification; Child; depression & mood disorders; Depression - therapy; Goal setting; Health care access; Hospitals; Humans; Intervention; Mental depression; Mental disorders; Mental Health; Patients; Pediatrics; Psychotropic drugs; Quality of Life; Questionnaires; Randomized Controlled Trials as Topic; Self report; Suicides & suicide attempts; Teenagers; Telemedicine; Therapy; Treatment Outcome; Young Adult; Young adults
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-067141

IntroductionThere are unmet mental health needs of depressed adolescents and young adults (AYAs) across the USA. Behavioural technology adequately integrated into clinical care delivery has potential to improve care access and efficiency. This multisite randomised controlled trial evaluates how a coach-enhanced digital cognitive behavioural intervention (dCBI) enhances usual care for depressed AYAs in paediatric practices with minority enriched samples.Methods and analysisParticipants (n=750) ages 16–22 who meet threshold criteria for depressive severity (Patient Health Questionnaire-9; PHQ-9 score 10-24) will be recruited through paediatric practices across three academic institutions (Boston, Pittsburgh and San Diego). Participants will be randomised to 12 weeks of dCBI+treatment as usual (TAU) (n=450) or TAU alone (n=300) in outpatient paediatric practices. Assessments will be completed at baseline, 6 weeks and 12 weeks with the primary outcome being improvement in clinician-rated and self-reported depressive severity (Children’s Depression Rating Scale—Revised and PHQ-9) and secondary outcomes being self-reported suicidal ideation (item 9 on PHQ-9), anxiety severity (Generalised Anxiety Disorder), general quality of life (Satisfaction with Life Scale) and general functioning (Children’s Global Assessment Scale). The study design is an intent-to-treat mixed effects regression with group, and covariates nested within the sites.Ethics and disseminationAll participants or their parent/guardian (under 18 years or unemancipated) will give informed consent to a study team member. All data are expected to be collected over 18 months. The Institutional Review Board (IRB) is a board at each institution in the United States that reviews and monitors research involving human subjects. IRB approval from the University of Pittsburgh was obtained on 30 November 2021 (STUDY21080150), from the University of California San Diego’s Human Research Protection Program IRB on 14 July 2022 (802047), and from the Boston Children’s Hospital IRB on 25 October 2022 (P00040987). Full study results are planned to be published within 2 years of initial study recruitment (October 2024). Dissemination of findings will occur in peer-reviewed journals, professional conferences and through reports to participating entities and stakeholders.Trial registration numberNCT05159713; ClinicalTrials.gov